Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

被引:47
|
作者
Ninan, Jem [1 ]
Anh-Minh Nguyen [3 ]
Cole, Antonia [1 ]
Rischmueller, Maureen [1 ]
Dodd, Thomas [4 ]
Roberts-Thomson, Peter [5 ]
Hill, Catherine L. [1 ,2 ]
机构
[1] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
[2] Univ Adelaide, Hlth Observ, Woodville, SA, Australia
[3] Dept Hlth, Hlth Stat Unit, Woodville, SA, Australia
[4] SA Pathol, Dept Tissue Pathol, Woodville, SA, Australia
[5] Flinders Med Ctr, Dept Allergy Immunol & Arthrit, Woodville, SA, Australia
关键词
MORTALITY RATE; GIANT CELL ARTERITIS; BIOPSY-PROVEN; TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; SURVIVAL;
D O I
10.3899/jrheum.101254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented. Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002). Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215-17; doi:10.3899/jrheum.101254)
引用
收藏
页码:2215 / 2217
页数:3
相关论文
共 50 条
  • [1] Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study
    Saleh, Muna
    Turesson, Carl
    Englund, Martin
    Merkel, Peter A.
    Mohammad, Aladdin J.
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (08) : 1559 - 1565
  • [2] Cancer in biopsy-proven giant cell arteritis.: A population-based study
    Gonzalez-Gay, Miguel A.
    Lopez-Diaz, Maria J.
    Martinez-Lado, Luciana
    Pena-Sagredo, Jose L.
    Lopez-Agreda, Hugo
    Miranda-Filloy, Jose A.
    Gonzalez-Juanatey, Carlos
    Sanchez-Andrade, Arnalia
    Martin, Javier
    Llorca, Javier
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2007, 37 (03) : 156 - 163
  • [3] Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study
    Macchioni, Pierluigi
    Boiardi, Luigi
    Muratore, Francesco
    Restuccia, Giovanna
    Cavazza, Alberto
    Pipitone, Nicolo
    Catanoso, Mariagrazia
    Mancuso, Pamela
    Luberto, Ferdinando
    Rossi, Paolo Giorgi
    Salvarani, Carlo
    RHEUMATOLOGY, 2019, 58 (04) : 609 - 616
  • [4] Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study
    Muratore, F.
    Crowson, C. S.
    Boiardi, L.
    Pinelli, A.
    Koster, M. J.
    Restuccia, G.
    Kermani, T. A.
    Matteson, E. L.
    Salvarani, C.
    Warrington, K. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (02) : S79 - S83
  • [5] Thrombocytosis in patients with biopsy-proven giant cell arteritis
    Foroozan, R
    Danesh-Meyer, H
    Savino, PJ
    Gamble, G
    Mekari-Sabbagh, ON
    Sergott, RC
    OPHTHALMOLOGY, 2002, 109 (07) : 1267 - 1271
  • [6] Atherosclerosis in patients with biopsy-proven giant cell arteritis
    Gonzalez-Juanatey, Carlos
    Lopez-Diaz, Maria J.
    Martin, Javier
    Llorca, Javier
    Gonzalez-Gay, Miguel A.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (08): : 1481 - 1486
  • [7] Relapses and Recurrences in Giant Cell Arteritis A Population-Based Study of Patients With Biopsy-Proven Disease From Northwestern Spain
    Martinez-Lado, Luciana
    Calvino-Diaz, Carolina
    Pineiro, Angela
    Dierssen, Trinidad
    Vazquez-Rodriguez, Tomas R.
    Miranda-Filloy, Jose A.
    Lopez-Diaz, Maria J.
    Blanco, Ricardo
    Llorca, Javier
    Gonzalez-Gay, Miguel A.
    MEDICINE, 2011, 90 (03) : 186 - 193
  • [8] Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain -: A population-based study
    Gonzalez-Gay, MA
    Garcia-Porrua, C
    Piñeiro, A
    Pego-Reigosa, R
    Llorca, J
    Hunder, GG
    MEDICINE, 2004, 83 (06) : 335 - 341
  • [9] Epidemiology of biopsy-proven giant cell arteritis in South Australia
    Dunstan, E.
    Lester, S. L.
    Rischmueller, M.
    Dodd, T.
    Black, R.
    Ahern, M.
    Cleland, L. G.
    Roberts-Thomson, P.
    Hill, C. L.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (01) : 32 - 39
  • [10] Mortality in giant cell arteritis: analysis of a monocentric cohort of biopsy-proven patients
    Talarico, R.
    Figus, M.
    D'Ascanio, A.
    Stagnaro, C.
    Ferrari, C.
    Elefante, E.
    Tani, C.
    Baldini, C.
    Mosca, M.
    Bombardieri, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (01) : S90 - S90